Zydus Cadila gets USFDA nod for bowel disease drug Mesalamine suppositories
"Zydus Cadila has received the final approval from the USFDA to market Mesalamine Suppositories for rectal use...1000 mg," the drug firm said in a regulatory filing.
New Delhi: Zydus Cadila on Thursday said it has got final approval from the US health regulator to market Mesalamine suppositories. The drug is used to treat ulcerative proctitis, a type of bowel disease.
"Zydus Cadila has received the final approval from the USFDA to market Mesalamine Suppositories for rectal use...1000 mg," the drug firm said in a regulatory filing.
Also Read: Zydus Cadila Gets USFDA Nod For Fluocinonide Cream To Treat Skin Conditions
Mesalamine Suppositories is an aminosalicylate anti-inflammatory drug and is believed to work by blocking the production of certain natural chemicals that may cause pain and swelling.
This will be manufactured at the group's topical manufacturing facility at Ahmedabad.
The group now has 280 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.
Also Read: Zydus Cadila Gets DGCI Nod For Diabetes Drug Saroglitazar Magnesium
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd